60 Degrees Pharma
- Company typePublic
- Founded2010
- HeadquartersWashington, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
60 Degrees Pharma firmographics
Firmographics- Name
- 60 Degrees Pharma
- Legal name
- 60 Degrees Pharmaceuticals, Inc.
- Website
- https://60degreespharma.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
60 Degrees Pharma industry classification
Industry- Product category
- Infectious disease pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
- akta.pro secondary industries
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA)
Keywords
Where 60 Degrees Pharma is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
60 Degrees Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Pharmaceutical Product Sales: Revenue from sales of FDA-approved ARAKODA (tafenoquine) for malaria prevention in the U.S. and Australia markets. Product revenues grew 65% to $1.005 million in 2025.
- Capital Raises: Public offerings and private placements to fund operations, R&D, and commercialization activities. The company raised $5 million gross in July 2025, $4 million in September 2024, and $2.4 million in January 2024.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Standard prescription pricing through GoodRx |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels4 records
60 Degrees Pharma product offering
Product offeringCore offering
60 Degrees Pharmaceuticals develops and commercializes prescription medicines for the treatment and prevention of infectious diseases. Its lead commercial product is ARAKODA (tafenoquine), an FDA-approved once-weekly malaria prophylaxis tablet marketed in the U.S. and Australia (as KODATEF). The pipeline extends tafenoquine to chronic babesiosis and fungal infections, celgosivir to dengue and respiratory viruses, and a castanospermine-based non-prescription dietary supplement under exclusive license from Florida State University.
Product overview
60 Degrees Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing medicines for infectious diseases. The company's lead product is ARAKODA (tafenoquine), an FDA-approved once-weekly malaria prevention medication commercially available in the U.S. and Australia. The pipeline includes tafenoquine for additional indications (babesiosis treatment, fungal diseases), celgosivir for dengue and respiratory viruses, and Australian Chestnut Extract as a dietary supplement. The company operates through global partnerships for distribution and clinical development.
Differentiator
Problem solved
Functional benefit
Brands
- ARAKODA: FDA-approved tafenoquine tablets for malaria prevention
- KODATEF
Products and services
- ARAKODA (tafenoquine) FDA-approved once-weekly prescription medication for malaria prevention in U.S. travelers visiting endemic regions, featuring a 16-day half-life and a required three-day loading phase before travel.
- KODATEF (tafenoquine) Tafenoquine product approved by the Australian Therapeutic Goods Administration for malaria prevention, distributed exclusively in Australia through Biocelect.
- Tafenoquine for babesiosis treatment Pipeline indication evaluating tafenoquine in Phase 2 proof-of-concept clinical trials for treatment of babesiosis, a tick-borne parasitic disease for which no FDA-approved treatment exists.
- Celgosivir Host-targeted glucosidase inhibitor being developed for treatment of dengue fever and respiratory viruses including RSV and COVID-19, repositioned from prior HIV and hepatitis C programs.
- Australian Chestnut Extract (Castanospermine) Dietary Supplement Botanical supplement candidate for non-prescription use based on castanospermine extracted from Australian Chestnut seeds, under exclusive license from Florida State University.
Quantifiable outcome
- Approximately 100% cure rate in immunosuppressed patients with relapsing babesiosis when weekly tafenoquine is added to standard atovaquone-containing combination regimens
- +2 more outcomes
Companies that use 60 Degrees Pharma
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
60 Degrees Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
60 Degrees Pharma partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Florida State UniversitycoreExclusive patent licensing agreement to develop large-scale extraction techniques for castanospermine from Australian Chestnut seeds for non-prescription dietary supplement use. Company plans to meet with FDA on July 1, 2026 regarding NDIN filing.
- GoodRxcorePartnership to improve affordability and accessibility of ARAKODA, allowing eligible patients to save up to 30% at over 70,000 pharmacies nationwide. Discounted pricing available starting February 2, 2026.
- Runway HealthcoreTelehealth partnership to expand access to ARAKODA through direct-to-patient platform launching April 2, 2026. Enables eligible travelers to receive physician-led online consultations and home delivery of prescribed medication matched to their travel itinerary.
- North Carolina State UniversityminorResearch collaboration on Babesia infection in chronic fatigue patients. Study found 24% of 50 patients with chronic fatigue tested positive for Babesia. Published in Pathogens journal and funded by 60 Degrees Pharmaceuticals.
- Mount Sinai Icahn School of MedicinecoreClinical trial site for B-FREE Chronic Babesiosis Study evaluating tafenoquine efficacy and safety in treating chronic babesiosis patients with severe fatigue.
- Walter Reed Army Institute of Research / U.S. ArmycoreLicensed technology from U.S. Army for tafenoquine development. US Army-supported $18+ million development program. Cooperative research and development agreement secured commercialization rights for malaria prophylaxis.
- Duke-NUS Medical School / SingHealthminorExclusive licensing deal to further develop celgosivir for dengue fever. Phase I clinical study demonstrated safety in dengue patients with trend toward faster NS1 clearance.
- BiocelectcoreAustralian distribution partner for ARAKODA/KODATEF. Level 4, 143 Macquarie St, Sydney NSW 2000, Australia. Company commercially launched KODATEF in Australia in September 2018.
- Scandinavian Biopharma Distribution ABminorInternational operations partner in Scandinavia. Located at Industrivägen 1 171 48 Solna, Sweden.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
60 Degrees Pharma competitors and assessment
Company assessmentDirect peers
- Bavarian Nordic: Bavarian Nordic is a specialty infectious disease vaccine company (JYNNEOS for mpox/smallpox, tick-borne encephalitis vaccine) that built its business on licensed government/military-originated technologies. Mirrors 60P's strategy of licensing military-developed assets (tafenoquine from Walter Reed) for commercial development in infectious diseases.
- BioCryst Pharmaceuticals: BioCryst markets Krintafel (tafenoquine) for radical cure of P. vivax malaria, using the same tafenoquine molecule that 60P markets as ARAKODA for prevention. Both companies are small specialty infectious disease pharma firms developing tafenoquine-based products, making them the closest direct peer despite targeting different malaria indications.
- Atea Pharmaceuticals: Atea Pharmaceuticals is a small clinical-stage infectious disease company developing antivirals, including for dengue and respiratory viruses. Overlaps with 60P's celgosivir program for dengue and respiratory viruses, and shares the small-cap infectious disease specialty pharma profile.
- ANI Pharmaceuticals: ANI Pharmaceuticals is a small specialty pharmaceutical company focused on niche generics, branded specialty, and rare disease products. It offers a comparable profile to 60P as a small public specialty pharma with a focused portfolio, government channel exposure, and ongoing pipeline expansion through in-licensing.
- SIGA Technologies: SIGA Technologies is a small specialty infectious disease pharmaceutical company that developed TPOXX (tecovirimat) for smallpox under FDA Priority Review and government stockpiling contracts. It mirrors 60P's profile as a niche infectious disease pharma with a single FDA-approved drug and government/military channel exposure.
- Citius Pharmaceuticals: Citius Pharmaceuticals is a small specialty pharma developing and commercializing critical care and infectious disease products, listed on Nasdaq. It shares the micro-cap, single-product or narrow-pipeline profile, late-stage clinical pipeline, and ongoing capital-raise cadence typical of small specialty infectious disease pharma.
Broad incumbents
- GSK (GlaxoSmithKline): GSK markets Malarone (atovaquone/proguanil), the leading daily-dose malaria prophylaxis, and the Mosquirix malaria vaccine. GSK competes directly with ARAKODA in malaria prevention via its widely-used daily alternative, making it the most relevant broad incumbent competitor despite vastly greater scale.
- Emergent BioSolutions: Emergent BioSolutions is a broader infectious disease and public health preparedness company selling vaccines, therapeutics, and devices to government and commercial customers. Comparable to 60P through its infectious disease focus, government/military channel, and biologics/small molecule franchise, though at significantly larger scale.
- Sanofi: Sanofi Pasteur is a major vaccine and tropical disease pharmaceutical manufacturer, with malaria programs, traveler vaccines, and a global public health infectious disease franchise. It represents the broad incumbent in tropical/infectious disease pharma against which 60P's ARAKODA competes for traveler and institutional segments.
- Lupin Pharmaceuticals: Lupin manufactures and distributes generic antimalarials, including generic atovaquone/proguanil and other malaria prevention and treatment products. As a generic competitor to ARAKODA's branded positioning, Lupin is the broad incumbent that most directly competes on price in malaria prophylaxis channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks3 records
Key highlights6 records
Customer concentration
60 Degrees Pharma social profiles
Digital presence60 Degrees Pharma compliance and trust
Trust signalCompliance2 records
60 Degrees Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
60 Degrees Pharma leadership team
Management profileNumber of profiles
Profiles9 records
60 Degrees Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
60 Degrees Pharma funding detail
Funding detailFunding overview
Funding rounds8 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
60 Degrees Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 60 Degrees Pharma
What does 60 Degrees Pharma do?
60 Degrees Pharmaceuticals develops and commercializes prescription medicines for the treatment and prevention of infectious diseases. Its lead commercial product is ARAKODA (tafenoquine), an FDA-approved once-weekly malaria prophylaxis tablet marketed in the U.S. and Australia (as KODATEF). The pipeline extends tafenoquine to chronic babesiosis and fungal infections, celgosivir to dengue and respiratory viruses, and a castanospermine-based non-prescription dietary supplement under exclusive license from Florida State University.
Is 60 Degrees Pharma a public or private company?
60 Degrees Pharma is a public company. It is classified as public and is currently operating.
When was 60 Degrees Pharma founded?
60 Degrees Pharma was founded in 2010. It employs 1 to 10 people.
Where is 60 Degrees Pharma based?
60 Degrees Pharma is headquartered in Washington, United States, in the North America region.
How does 60 Degrees Pharma make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are capital Raises.
Who are 60 Degrees Pharma's main competitors?
Direct peers on record are Bavarian Nordic, BioCryst Pharmaceuticals, Atea Pharmaceuticals, ANI Pharmaceuticals, SIGA Technologies and Citius Pharmaceuticals. Broad incumbents are GSK (GlaxoSmithKline), Emergent BioSolutions, Sanofi and Lupin Pharmaceuticals.
Does 60 Degrees Pharma have an API?
No public API is recorded for 60 Degrees Pharma.
What industry is 60 Degrees Pharma in?
60 Degrees Pharma's product category is Infectious disease pharmaceuticals. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.